ClinicalTrials.gg
RecruitingNCT07288918Updated Oct 21, 2026

The Effect of Education on Quality of Life, Adherence to Immunosuppressive Therapy and Symptom Control in Organ Transplant Patients

An interventional study of Mobile application installation and Providing teaching booklets in Organ Transplantation, Mobile Applications and Nursing, sponsored by Ondokuz Mayıs University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Ondokuz Mayıs University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 21, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Organ transplantation is the most effective method for treating end-stage organ failure and allows patients on the verge of death to continue living. Organ transplantation involves removing all or part of an organ or tissue from the body and transplanting it to suitable patients experiencing failure. Therefore, transplants are performed to treat diseases, save lives, improve patients' quality of life, and extend their life expectancy. The World Health Organization (WHO) defines quality of life as individuals' perceptions of their goals, expectations, standards, and concerns regarding their place in life, within the context of the culture and value systems they live in. Achieving an adequate quality of life after transplantation is considered an indicator of therapeutic success, which is increasingly important to measure by the transplant care team.

Individuals who undergo transplantation and their families often perceive transplantation as a rebirth. However, 30% to 40% of patients report no better health-related quality of life after kidney transplantation compared to dialysis. This is attributed to frequent checkups and monitoring, new medications and their strict dosing schedules, and the unexpected discomfort of potential side effects.

Even after the psychological challenges of waiting and the joy of a successful transplant, transplant recipients take on new responsibilities. Problems such as accepting transplantation risks, acute and chronic organ rejection, and adherence to lifelong medication regimens can arise. Persistent side effects of various immunosuppressive agents, adaptation and maintenance of the new organ, and uncertainty about the future due to rejection of transplanted organs and the subsequent re-transplantation process can all lead to physical and psychological distress.

Immunosuppressive therapy represents a lifelong endeavor for transplant recipients. These medication regimens involve complex protocols, not only due to the number of pills required, but also due to blood level monitoring, side effects, and frequent dose adjustments to avoid rejection. Non-adherence to immunosuppressant regimens has been shown to be high in organ transplant patients. Non-adherence rates in this population are reported as high as 65%. The highest immunosuppressant non-adherence rate is found in kidney transplant recipients, with a prevalence of 36-55%, while this rate is 15-40% in liver transplant recipients. Studies have found that 16-36% of graft losses are associated with non-adherence. The ever-growing population of transplant recipients and the limited number of transplant centers, particularly those living farther away, necessitate innovative healthcare delivery models to monitor and improve the use of transplant center resources. With the advent of smartphones and mobile medical devices, mobile health has become a popular way for healthcare professionals to manage patient care. Mobile health can serve as an adjunct method for delivering health education information, sending reminders to patients to take their medications, and implementing online education. In particular, converting paper-based education to video format can significantly increase knowledge on various topics. It is necessary to address the problems and challenges patients face after discharge and the practices that can potentially address these issues. These results suggest that healthcare professionals can do more to provide comprehensive care to patients, promote successful home-based treatment regimens, symptom control, and quality of life.

02

Conditions studied

  • Organ Transplantation
  • Mobile Applications
  • Nursing
03

In context

Lead sponsor

Ondokuz Mayıs University is the lead sponsor of 281 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being over 18 years of age,
  • Having undergone a liver or kidney transplant for the first time,
  • Having been discharged at least three months ago,
  • Having access to a smartphone and internet and the ability to use them independently,

Exclusion criteria

Exclusion Criteria:

  • Having a diagnosis of a psychiatric or neurological disorder,
  • Having hearing or vision problems severe enough to impede communication,
  • Requesting to leave during the research period
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Mobile applications

    Other: Mobile application installation

  • Experimental
    Teaching booklet

    Other: Providing teaching booklets

  • Active comparator
    Control

    Other: Control

Interventions

  • OtherMobile application installation

    Transplant patients will receive standard discharge training. A mobile application created by the researcher will be installed on transplant patients' phones.

  • OtherProviding teaching booklets

    Transplant patients will receive standard discharge training. Transplant patients will be given researcher prepared instructional booklet

  • OtherControl

    Transplant patients will receive standard discharge training

06

What researchers measure

Primary outcomes

  1. The effect of education on quality of life in organ transplant patients

    The SF-36 Quality of Life Scale will be administered before the training intervention. Most questions on the scale use Likert-type rating scales (3, 5, and 6 points), while questions four and five can be answered with yes/no. Each section of the scale is rated between 0 and 100 points. Higher scores indicate better health, or improved quality of life ("0" for poor health, "100" for good health).

    Time frame: Baseline, and 1, 3, and 6 months post-intervention.

  2. The effect of education on symptom control in organ transplant patients

    The Modified Transplant Symptom Occurrence and Symptom Distress Scale-59 will be administered before the training intervention. Each item on the scale corresponds to a side effect of immunosuppressive drugs, and these items have two dimensions that assess symptom occurrence and discomfort level. Symptom occurrence is scored from 1 to 5, with 1=never occurring and 5=always occurring. Symptom discomfort level is scored from 0 to 4, with 0=never causing discomfort and 4=causing extreme discomfort.

    Time frame: Baseline, and 1, 3, and 6 months post-intervention.

  3. The effect of education on adherence to ımmunosuppressive therapy in organ transplant patients

    The Immunosuppressant Therapy Adherence Scale in Organ Transplantation Patients will be administered before the training intervention. The scale consists of four questions, and participants can receive a score between 0 and 12. Individuals who have not forgotten their immunosuppressive treatment in the last three months are given 3 points, those with 1-20% non-adherence to immunosuppressive treatment are given 2 points, those with 21-50% non-adherence to immunosuppressive treatment are given 1 point, and those with \>50% non-adherence to immunosuppressive treatment are given 0 points.

    Time frame: Baseline, and 1, 3, and 6 months post-intervention.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Mar 2026 → Jan 2027 and completion Aug 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 17, 2025
StartActual
Dec 10, 2025
Primary completionEst.
Jan 1, 2027was Mar 2026
CompletionEst.
May 30, 2027was Aug 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
Ondokuz Mayis University is now Recruiting
Oct 21, 2026
Primary completion
Mar 10, 2026→Jan 1, 2027
Oct 21, 2026
Study completion
Aug 30, 2026→May 30, 2027
Oct 21, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Ondokuz Mayis University · Samsun, Turkey (Türkiye)Contact added r•••@gmail.com · •••4895
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    Ondokuz Mayis University is now Recruiting
    Primary completion Mar 10, 2026→Jan 1, 2027
    Study completion Aug 30, 2026→May 30, 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Ondokuz Mayis University · Samsun, Turkey (Türkiye)Contact added r•••@gmail.com · •••4895
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07288918
Responsible party
Rıfat GÜRKAN (Principal Investigator, Ondokuz Mayıs University) — Principal investigator
First posted
Dec 17, 2025
Start date
Dec 10, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Rıfat GÜRKAN, Master of Science in Nursing
Contact
rifatgurkannn@gmail.com
+905067154895

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion